American Journal of Clinical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7)
Conclusions: In our real world experience after progression to IO, vascular endotelial groth factor-tyrosine kinase inhibitors, given to patients, proved to be active and safe choices. Cabozantinib was associated with a better outcome in terms of median PFS. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - March 1, 2021 Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research

Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy
Conclusions: Understanding demographic and clinical risk factors for ER/IP care among patients on ICIs can help highlight disparities, prospectively identify high-risk patients, and inform preventive programs aimed at reducing such care. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - March 1, 2021 Category: Cancer & Oncology Tags: Original Articles: Immunotherapy Source Type: research

Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature
Conclusion: Larger prospective studies are needed in order to define a consensus on the use of vaccines under immunotherapy. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - March 1, 2021 Category: Cancer & Oncology Tags: Original Articles: Immunotherapy Source Type: research

Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety
Conclusions: This multicenter study, albeit retrospective, demonstrates the activity of this combination as third-line chemotherapy option in a challenging clinical setting such as triple-negative or hormone-resistant patients with breast cancer progressing after several lines of hormonal manipulations. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - March 1, 2021 Category: Cancer & Oncology Tags: Original Articles: Breast Source Type: research

Postoperative Observation Versus Radiotherapy for Pathologic N1 Oral Cavity Squamous Cell Carcinoma
Conclusions: PORT was associated with a survival benefit compared with observation. Notably, pN1 was an adverse risk factor relative to pN0 if, and only if, patients did not receive PORT, suggesting pN1 by itself may be an indication for PORT. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - March 1, 2021 Category: Cancer & Oncology Tags: Original Articles: Head and Neck Source Type: research

Second-line Chemotherapy Prolongs Survival in Real World Patients With Advanced Biliary Tract and Gallbladder Cancers: A Multicenter Retrospective Population-based Cohort Study
Conclusions: This well-designed population-based retrospective cohort study suggests that second-line chemotherapy improves survival of real world patients with advanced biliary tract and gallbladder cancers and should be offered to the patients who are potential candidates for chemotherapy. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - March 1, 2021 Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research

“Was It Worth It?” A Pilot Study in Patient Perspectives on the Worthwhileness of Radiation Therapy: Erratum
No abstract available (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - January 28, 2021 Category: Cancer & Oncology Tags: Erratum Source Type: research

Clinical Trials Before, During, and After COVID-19 Pandemic
No abstract available (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - January 28, 2021 Category: Cancer & Oncology Tags: Letter to the Editor Source Type: research

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status
Conclusion: These results suggest that advanced BRAFV600 wild-type melanoma patients have worse survival than BRAFV600-mutated patients during the first 10 months after diagnosis because of less available treatment options. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - January 28, 2021 Category: Cancer & Oncology Tags: Original Articles: Cutaneous Source Type: research

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody
This study aims to determine the impact of sarcopenia, body mass index (BMI), and inflammatory biomarkers on survival in advanced hepatocellular carcinoma (HCC) patients treated with anti-PD-1 antibody-based immunotherapy. Methods: A retrospective review of advanced HCC patients treated with immunotherapy at Winship Cancer Institute between 2015 and 2019 was performed. Baseline computed tomography and magnetic resonance images were collected at mid-L3 level, assessed for skeletal muscle density using SliceOmatic (TomoVision, version 5.0) and converted to skeletal muscle index (SMI) by dividing it by height (m2). Sex...
Source: American Journal of Clinical Oncology - January 28, 2021 Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research

Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens
Conclusions: Mutations in DDR genes were present in 22% of patients with mCRC. In patients with DDR-mutated tumors, initial treatment with FOLFOX/XELOX correlated with improved OS and a numerically higher RR compared with FOLFIRI. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - January 28, 2021 Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research

Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy
The objective of this study was to assess the association between pretreatment p53, hypoxia inducible factor 1a (HIF1a), Ki-67, carbonic anhydrase-9 (CA-9), and glucose transporter 1 (GLUT1) expression in locally advanced cervical cancer patients treated definitively with concurrent chemoradiation therapy (CRT) and treatment outcomes including overall survival (OS), progression-free survival (PFS), local-regional control (LC), and distant metastases–free survival (DMFS). Patients and Methods: Twenty-eight patients treated definitively and consecutively for cervical cancer with CRT had p53, HIF1a, Ki-67, CA-9, and ...
Source: American Journal of Clinical Oncology - January 28, 2021 Category: Cancer & Oncology Tags: Original Articles: Gynecologic Source Type: research

Expansion of the LabBM Score: Is the LabPS the Best Tool Predicting Survival in Patients With Brain Metastases?
Conclusions: Integration of blood biomarkers should be considered when attempting to develop improved scores. Additional research is needed to improve the tools which predict short survival, because many of these patients continue to go undetected with all available scores. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - January 28, 2021 Category: Cancer & Oncology Tags: Original Articles: Central Nervous System Source Type: research

Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial
Conclusions: The maximum tolerated dose of nal-IRI was 50 mg/m2 every 2 weeks with TMZ 50 mg/m2/d. The dose-limiting toxicities were diarrhea and neutropenia. No activity was seen at interim analysis and the study was terminated. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - January 28, 2021 Category: Cancer & Oncology Tags: Original Articles: Central Nervous System Source Type: research

Journey to Diversity in a University Radiation Oncology Residency Program: The Role of Leadership and Target Goals
Conclusions: Our experience provides a model to measure diversity and track performance over time in residency programs, departments, or practice groups. The priority to place on diversity, and specific performance goals, vary by group. For those seeking to increase diversity, our experience shows it is possible to achieve substantial diversity in all categories, but change requires leadership making diversity a priority. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - January 28, 2021 Category: Cancer & Oncology Tags: Original Articles: Education Source Type: research